Diffusive vs. convective therapy: Effects on mediators of inflammation in patients with severe systemic inflammatory response syndrome

Critical Care Medicine

Volumn 26, Issue 12, 1998, Pages 1995-2000

  Kellum, John A ^a   Johnson, John P ^a   Kramer, David ^a   Palevsky, Paul ^a   Brady, John J ^a   Pinsky, Michael R ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Acute renal failure; Blood purification; Continuous venovenous hemodialysis; Continuous venovenous hemofiltration; Cytokines; Hemodialysis; Hemofiltration; Sepsis; Systemic immune response syndrome; Tumor necrosis factor

Indexed keywords

CYTOKINE; ENDOTOXIN; INTERLEUKIN 10; INTERLEUKIN 6; SELECTIN; TUMOR NECROSIS FACTOR ALPHA;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIALYSIS; HEMODIALYSIS; HEMOFILTRATION; HUMAN; INFLAMMATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; ULTRAFILTRATION;

CONVECTION; CROSS-OVER STUDIES; DIFFUSION; ENDOTOXINS; HEMODIAFILTRATION; HEMOFILTRATION; HUMANS; INTERLEUKIN-10; INTERLEUKIN-6; KIDNEY FAILURE, ACUTE; L-SELECTIN; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032414995     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-199812000-00027     Document Type: Article

References (33)

1. Ronco C, Barbacini S, Digito A, et al: Achievements and new directions in continuous renal replacement therapies. New Horiz 1995; 3:708-716
2. Bellomo R, Tipping P, Boyce N: Continuous veno-venous hemofiltration with dialysis removes cytokines from the circulation of septic patients. Crit Care Med 1993; 21:522-526
3. Tonnesen E, Hansen MB, Hohndorf K, et al: Cytokines in plasma and ultrafiltrate during continuous arteriovenous haemofiltration. Anaesth Intensive Care 1993; 21:752-728
4. Journois D, Pouard P, Greeley WJ, et al: Hemofiltration during continuous cardiopulmonary bypass in pediatric cardiac surgery. Anesthesiology 1994; 81:1181-1189
5. Bellomo R, Tipping P, Boyce N: Interleukin-6 and interleukin-8 extraction during continuous venovenous hemodiafiltration in septic acute renal failure. Renal Fail 1995; 17:45-54
6. Grootendorst AF, van Bommel EF, van Leengoed LA, et al: Infusion of ultrafiltrate from endotoxemic pigs depresses myocardial performance in normal pigs. J Crit Care 1993; 8: 161-169
7. Kellum JA, Bellomo R, Rothfield K, et al: Clearance of vasoactive mediators by continuous veno-venous hemofiltration in acute canine endotoxemia. Abstr. Am J Respir Crit Care Med 1996; 153:A838
8. Heideman SM, Ofenstein JP, Saraik AP: Efficacy of continuous arteriovenous hemofiltration in endotoxic shock. Circ Shock 1994; 44:183-187
9. Ronco C, Tetta C, Lupi A, et al: Removal of platelet aggregating factor in experimental continuous arteriovenous hemofiltration. Crit Care Med 1995; 23:99-107
10. Hirasawa H, Sugai T, Oda S, et al: Continuous hemodiafiltration can remove humoral mediators from the blood stream of patients with SIRS/MODS. Abstr. Blood Purif 1997; 15:136
11. Heering P, Morgera S, Schmitz G, et al: Cytokine removal and cardiovascular hemodynamics in septic patients with continuous venovenous hemofiltration. Intensive Care Med 1997; 23:288-296
12. Lee PA, Matson JR, Pryor RW, et al: Continuous arteriovenous hemofiltration therapy for Staphylococcus aureus-induced septicemia in immature swine. Crit Care Med 1993; 21: 914-924
13. Lingnau W, Javorsky F: Continuous hemofiltration improved multiple organ failure and outcome. Abstr. Crit Care Med 1995; 23:A106
14. Golper TA, Vincent HH, Gleason JR, et al: Drug removal during high efficiency and high-flux hemodialysis. Contemp Issues Nephrol 1993; 27:175-208
15. Vincent HH, Akcahuseyin E, Goessens WHF, et al: Drug clearance by continuous haemodiafiltration (CAVHD). Analysis of the sieving coefficient and mass transfer coefficients of diffusion. Blood Purif 1993; 11:99-107
16. Schetz M, Ferdinande P, Van den Berghe G, et al: Removal of pro-in-flammatory cytokines with renal replacement therapy: Sense or nonsense? Intensive Care Med 1995; 21:169-176
17. Bellomo R: Choosing a therapeutic modality: Hemofiltration vs. hemodialysis vs. hemodiafiltration. Seminars in Dialysis 1996; 9:88-92
18. Sigler MH, Manns M: Membranes and devices used in continuous renal replacement therapy. Seminars in Dialysis 1996; 9:98-106
19. Golper TA, Jacobs AA: Pumps utilized during continuous renal replacement therapy. Seminars in Dialysis 1996; 9:119-124
20. Palevsky PM: Continuous renal replacement therapy component selection: Replacement fluid and dialysis solutions. Seminars in Dialysis 1996; 9:107-111
21. Bone RC: Toward an epidemiology and natural history of SIRS. JAMA 1992; 268:3452-3455
22. Pinsky MR, Vincent JL, Deviere J, et al: Serum cytokine levels in human septic shock - Relation to multiple-system organ failure and mortality. Chest 1993; 103:565-575
23. Matuschak GM, Martinez LH: Sepsis syndrome: Pathogenesis, pathophysiology, and management. In: Pathophysiologic Foundations of Critical Care. Pinsky MR, Dhainaut J-FA (Eds). Baltimore, Williams and Wilkins, 1993, pp 170-187
24. Barton R, Cerra FB: The hypermetabolism multiple organ failure syndrome. Chest 1989; 96:1153-1161
25. Ziegler EJ, Fisher CJ, Sprung CL, et al: Treatment of Gram-negative bacteremia and septic shock with HA-IA human monoclonal antibody against endotoxin. N Engl J Med 1991; 324: 429-436
26. Fisher CJ Jr, Opal SM, Dhainaut JF, et al: Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. Crit Care Med 1993; 21:318-327
27. Fisher CJ Jr, Dhainaut JF, Opal SM, et al: Recombinant human interleukin-1 receptor antagonist in the treatment of patients with sepsis syndrome: Results from a randomized, double-blind, placebo controlled trial. JAMA 1994; 271:1836-1844
28. Dhainaut JF, Tenaillon A, Le Tulzo Y, et al: Platelet activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: A randomized, double-blind, placebo-controlled, multicenter clinical trial. Crit Care Med 1994; 22:1720-1728
29. Hirasawa H, Sugai T, Oda S, et al: Continuous hemodiafiltration can remove humoral mediators from the blood stream of patients with SIRS/MODS. Abstr. Blood Purif 1997; 15:136
30. van Bommel EFH, Hesse CJ, Jutte NHPM, et al: Cytokine kinetics (TNF-α, IL-β, IL-6) during continuous hemofiltration: A laboratory and clinical study. Contrib Nephrol 1995; 116:62-75
31. Langsdorf LJ, Zydney AL: Effect of blood contact on the transport properties of hemodialysis membranes: A two-layer membrane model. Blood Purif 1994; 12:292-307
32. Schmitz ML, Baeuerle PA: Multi-step activation of NF-kappa B/Rel transcription factors. Immunobiology 1995; 193:116-127
33. Grootendorst AF, van Bommel EF, van Leengoed LA, et al: High volume hemofiltration improves hemodynamics and survival of pigs exposed to gut ischemia and reperfusion. Shock 1994; 2:72-78